Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|18|2|173-183

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.18, Iss.2, 2018-01, pp. : 173-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

P53 Mdm2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 18, Iss. 30, 2012-10 ,pp. : 4668-4678

Bentham Science Publishers

Access to resources Recommend Favorite

Nanoparticles Loaded with Nutlin-3 Display Cytotoxicity Towards p53 wild–type JVM-2 But Not Towards p53 mutated BJAB Leukemic Cells

By  

Current Medicinal Chemistry, Vol. 20, Iss. 21, 2013-07 ,pp. : 2712-2722

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecule Inhibitors of the p53-MDM2

By  

Current Medicinal Chemistry, Vol. 15, Iss. 17, 2008-07 ,pp. : 1720-1730

Bentham Science Publishers

Access to resources Recommend Favorite

Reactivation of p53 by Inhibiting Mdm2 E3 Ligase: A Novel Antitumor Approach

By  

Current Cancer Drug Targets, Vol. 11, Iss. 8, 2011-10 ,pp. : 987-994

Bentham Science Publishers

Access to resources Recommend Favorite

The Docking Based 3D-QSAR Studies on Isoindolinone Derived Inhibitors of p53-MDM2 Binding

By  

Letters in Drug Design & Discovery, Vol. 11, Iss. 1, 2014-01 ,pp. : 50-58

Bentham Science Publishers

Access to resources Recommend Favorite